DNAprint Genomics (DNAG)

[ann441j]

As posted by worktoplay on IV:

...Looks to me like they're beginning development of another drug, this one an EPO inhibitor. I don't know what specific neuro or cardio protective effects they anticipate, but with Sytkowski being an expert in the field, I'm certain they have something specific in mind.

R103A is a modified EPO. The "103A" stands for a substitution of Alanine for Arginine at site 103 of the molecule. It has been studied already as with application in sickle cell disease.

Here's a link to some prior work. It takes a few seconds to load but the full PDF comes up eventually:

http://www.bloodjournal.org/cgi/reprint/99/12/4400

Ann